Nothing Special   »   [go: up one dir, main page]

AR077014A1 - Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer - Google Patents

Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Info

Publication number
AR077014A1
AR077014A1 ARP100102003A ARP100102003A AR077014A1 AR 077014 A1 AR077014 A1 AR 077014A1 AR P100102003 A ARP100102003 A AR P100102003A AR P100102003 A ARP100102003 A AR P100102003A AR 077014 A1 AR077014 A1 AR 077014A1
Authority
AR
Argentina
Prior art keywords
ftalazine
cancer
prepare
treatment
disposed
Prior art date
Application number
ARP100102003A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR077014A1 publication Critical patent/AR077014A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicacion 1: Un compuesto derivado de ftalazina 1,4-disustituida caracterizado porque es de la formula (1) donde, R1 es hidrogeno o metilo; R2 es hidrogeno o metilo; y R3, R4, R5, R6, o R7 son independientemente hidrogeno, fluoro, cloro, ciano, trifluorometilo, trifluorometoxi, difluorometoxi, metilsulfonilo, o trifluorometilsulfonilo, siempre que al menos tres de R3, R4, R5, R6 y R7 sean hidrogeno; o una sal del mismo farmacéuticamente aceptable.
ARP100102003A 2009-06-19 2010-06-08 Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer AR077014A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21862809P 2009-06-19 2009-06-19

Publications (1)

Publication Number Publication Date
AR077014A1 true AR077014A1 (es) 2011-07-27

Family

ID=42332981

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102003A AR077014A1 (es) 2009-06-19 2010-06-08 Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Country Status (36)

Country Link
US (2) US8273742B2 (es)
EP (1) EP2443104B1 (es)
JP (1) JP5596139B2 (es)
KR (1) KR101389165B1 (es)
CN (1) CN102459233B (es)
AR (1) AR077014A1 (es)
AU (1) AU2010260244B2 (es)
BR (1) BRPI1011601A2 (es)
CA (1) CA2764542C (es)
CL (1) CL2011003147A1 (es)
CO (1) CO6480932A2 (es)
CR (1) CR20110658A (es)
DK (1) DK2443104T3 (es)
DO (1) DOP2011000386A (es)
EA (1) EA019059B1 (es)
EC (1) ECSP11011541A (es)
ES (1) ES2409054T3 (es)
HK (1) HK1164872A1 (es)
HN (1) HN2011003139A (es)
HR (1) HRP20130408T1 (es)
IL (1) IL216599A (es)
JO (1) JO2931B1 (es)
MA (1) MA33363B1 (es)
MX (1) MX2011014029A (es)
MY (1) MY156667A (es)
NZ (1) NZ596882A (es)
PE (1) PE20121050A1 (es)
PL (1) PL2443104T3 (es)
PT (1) PT2443104E (es)
SG (1) SG177289A1 (es)
SI (1) SI2443104T1 (es)
TN (1) TN2011000627A1 (es)
TW (1) TWI385165B (es)
UA (1) UA106755C2 (es)
WO (1) WO2010147917A1 (es)
ZA (1) ZA201108587B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7981892B2 (en) * 2008-04-29 2011-07-19 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
BRPI0921437A2 (pt) * 2008-11-03 2018-10-30 Lilly Co Eli antagonistas da via do hedgehog á base de fitalazina dissubstituída
MX2011005177A (es) 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
ES2446307T3 (es) * 2008-11-17 2014-03-07 Eli Lilly And Company Piridazinas tetrasustituidas antagonistas de la ruta de Hedgehog
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
CA2829755A1 (en) 2011-03-23 2012-09-27 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB201311953D0 (en) * 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
WO2015073691A1 (en) 2013-11-14 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of bmp signaling
CN105017140B (zh) * 2014-04-28 2017-12-29 复旦大学 邻氨基苯甲酰胺化合物及其制备方法和用途
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
AU2016271432A1 (en) * 2015-06-05 2017-12-07 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
IL261721B (en) 2016-03-15 2022-07-01 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
CN106279114B (zh) * 2016-08-04 2019-01-29 东南大学 一种Taladegib的合成方法
US10548908B2 (en) 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
CN106831718B (zh) * 2016-12-30 2019-05-07 上海科技大学 平滑受体配体及其应用
JP7323457B2 (ja) 2017-05-18 2023-08-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 肥満細胞疾患の処置のための方法及び医薬組成物
WO2021261601A1 (ja) 2020-06-26 2021-12-30 ラクオリア創薬株式会社 レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬
AU2021360767A1 (en) * 2020-10-13 2023-04-27 Endeavor Biomedicines, Inc. Methods of treating fibrosis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (es) 1977-06-03 1981-03-07 Pfizer
EP0876366B1 (en) 1996-01-15 2001-07-25 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines
CA2326654C (en) 1998-04-09 2010-11-09 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
ATE283700T1 (de) 1999-06-08 2004-12-15 Lorantis Ltd Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
EP1482928B1 (en) * 2001-07-27 2009-09-23 Curis, Inc. Mediators of hedgehog signaling pathways,compositions and uses related thereto
CA2483311A1 (en) * 2002-04-22 2003-10-30 Philip A. Beachy Modulators of hedgehog signaling pathways, compositions and uses related thereto
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
WO2006004589A2 (en) 2004-05-08 2006-01-12 Neurogen Corporation 3-aryl-5,6-disubstituted pyridazines
KR20200019263A (ko) 2004-09-02 2020-02-21 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
EP1900731A1 (de) * 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
MX2009009873A (es) * 2007-03-15 2009-09-24 Novartis Ag Compuestos organicos y sus usos.
EP2170866B1 (en) * 2007-06-25 2014-08-13 Amgen Inc. Phthalazine compounds, compositions and methods of use
US8222251B2 (en) 2007-09-07 2012-07-17 Amgen Inc. Pyridopyridazine compounds, compositions and methods of use
NZ586121A (en) * 2007-12-13 2012-03-30 Siena Biotech Spa Benzimidazole derivatives as hedgehog pathway antagonists and therapeutic applications thereof
US7981892B2 (en) 2008-04-29 2011-07-19 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
AU2009279760B2 (en) * 2008-08-04 2012-07-12 Amgen Inc. Aurora kinase modulators and methods of use
BRPI0921437A2 (pt) 2008-11-03 2018-10-30 Lilly Co Eli antagonistas da via do hedgehog á base de fitalazina dissubstituída
MX2011005177A (es) 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
ES2446307T3 (es) 2008-11-17 2014-03-07 Eli Lilly And Company Piridazinas tetrasustituidas antagonistas de la ruta de Hedgehog
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Also Published As

Publication number Publication date
PE20121050A1 (es) 2012-08-09
MA33363B1 (fr) 2012-06-01
HK1164872A1 (en) 2012-09-28
ZA201108587B (en) 2013-05-29
HRP20130408T1 (en) 2013-06-30
BRPI1011601A2 (pt) 2016-03-22
IL216599A (en) 2015-09-24
AU2010260244A1 (en) 2012-01-19
US20120316174A1 (en) 2012-12-13
PT2443104E (pt) 2013-05-07
PL2443104T3 (pl) 2013-08-30
CA2764542C (en) 2013-09-10
TN2011000627A1 (en) 2013-05-24
US9000023B2 (en) 2015-04-07
CA2764542A1 (en) 2010-12-23
EA019059B1 (ru) 2013-12-30
SG177289A1 (en) 2012-02-28
US20100324048A1 (en) 2010-12-23
US8273742B2 (en) 2012-09-25
SI2443104T1 (sl) 2013-07-31
CO6480932A2 (es) 2012-07-16
CL2011003147A1 (es) 2012-07-20
KR101389165B1 (ko) 2014-04-24
EP2443104B1 (en) 2013-04-17
JO2931B1 (en) 2015-09-15
MX2011014029A (es) 2012-02-21
CN102459233B (zh) 2014-07-02
WO2010147917A1 (en) 2010-12-23
TW201113268A (en) 2011-04-16
TWI385165B (zh) 2013-02-11
UA106755C2 (uk) 2014-10-10
CN102459233A (zh) 2012-05-16
EP2443104A1 (en) 2012-04-25
DK2443104T3 (da) 2013-05-06
JP2012530705A (ja) 2012-12-06
DOP2011000386A (es) 2012-02-29
NZ596882A (en) 2013-08-30
KR20120024783A (ko) 2012-03-14
ES2409054T3 (es) 2013-06-24
AU2010260244B2 (en) 2013-09-05
EA201270049A1 (ru) 2012-05-30
JP5596139B2 (ja) 2014-09-24
CR20110658A (es) 2012-02-20
IL216599A0 (en) 2012-03-01
MY156667A (en) 2016-03-15
ECSP11011541A (es) 2012-01-31
HN2011003139A (es) 2013-07-29

Similar Documents

Publication Publication Date Title
AR077014A1 (es) Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
BRPI1006115A8 (pt) "agentes indutores de apoptose para o tratamento de câncer e doenças autoimunes".
AR067540A1 (es) Compuesto de aril (isoxazol-4-il-metoxilo) , su uso para preparar un medicamento y composicion farmaceutica que lo comprende
AR071187A1 (es) Compuesto de arilmetil-tiazinamina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento de la enfermedad de alzheimer
MX367618B (es) Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos.
GT201200164A (es) "nuevos compuestos de espiropiperidina"
DOP2006000170A (es) Nuevos derivados de espirocromanona
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
BRPI0915084B8 (pt) composto, e, composição farmacêutica
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
CO6300945A2 (es) Compuestos fenil ftalazin - 1l piperidin - 4 - il benzamida o sales farmaceuticamente aceptables de los mismos, utiles como antagonistas de la trayectoria hedgehoc (hh)
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
CL2011000558A1 (es) Formas cristalinas de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; sal de sodio del compuesto, composicion farmaceutica que comprende la sal de sodio, util para tratar una infeccion por el virus de la hepatitis c.
AR077629A1 (es) Mimetico de smac
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
TN2015000084A1 (fr) Pyridinones bicycliques nouvelles
DK1885187T3 (da) Fremgangsmåde til behandling af lægemiddelresistent cancer
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
TR201902057T4 (tr) Tetrasiklin bileşikleri.

Legal Events

Date Code Title Description
FG Grant, registration